EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

EyePoint Pharmaceuticals Inc at HC Wainwright Ophthalmology Virtual Conference - Panel Discussion Transcript

Aug 16, 2023 / 03:00PM GMT
Release Date Price: €12.8
Yi Chen
H.C. Wainwright & Co., LLC - Analyst

Good morning, and thank you for joining the H.C. Wainwright's 3rd Annual Ophthalmology Virtual Conference. This is a panel discussion on sustained treatment for wet AMD. My name is Yi Chen, and I'm a healthcare research analyst at H.C. Wainwright.

Today, we have the pleasure of having Dr. Thomas Ciulla, Chief Medical Advisor, Retina and Chair of Scientific Advisory Board at Clearside Biomedical; and Dr. Jay Duker, President and CEO of EyePoint Pharmaceuticals; and Mr. Antony Mattessich, President and CEO of Ocular Therapeutix join us in this session. We also have the privilege of having Dr. Thanos Papakostas from Retina Institute join us as a key panelist. Welcome to the panel.

Questions & Answers

Yi Chen;Thanos Papakostas<
H.C. Wainwright & Co., LLC - Analyst

Dr. Papakostas, could you please give us a brief introduction of yourself and your practice? And more specifically, could you give us an overview of the current treatment paradigm for wet AMD in your practice?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot